- Thiogenesis Therapeutics Corp. (TTI) has announced its plan to undertake a non-brokered private placement for gross proceeds of up to $4,000,000
- The company will issue up to 8,000,000 common shares at a price of $0.50 per common share
- The company intends to use the proceeds from the offering to complete a good lab practices (GLP) study on absorption with its lead compound TTI-0102
- Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary based in San Diego, CA
- Thiogenesis Therapeutics Corp. was unchanged at $0.485 at 9:51 AM ET
Thiogenesis Therapeutics Corp. (TTI) has announced a non-brokered private placement for gross proceeds of up to $4,000,000.
The company will issue up to 8,000,000 common shares at a price of $0.50 per common share.
This offering is subject to the approval of the TSX Venture Exchange.
The company anticipates closing of the offering as soon as practicable, subject to receipt of all necessary regulatory approvals.
When issued, the offered shares will be subject to a four-month and one-day hold period pursuant to securities laws in Canada and, where applicable, the Exchange policies.
In connection with the offering, the company may pay finder’s fees to eligible persons in compliance with applicable securities laws and Exchange policies.
The company intends to use the proceeds from the offering to complete a good lab practices (GLP) study on absorption with its lead compound TTI-0102, reformulation work on TTI-0102 to make it viable in the form of a tablet or capsule, the purchase of inventory and general working capital purposes.
Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary based in San Diego, CA.
Thiogenesis Therapeutics Corp. was unchanged at $0.485 at 9:51 AM ET.
